tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Kezar Life Sciences Faces FDA Challenges in Drug Program
PremiumCompany AnnouncementsKezar Life Sciences Faces FDA Challenges in Drug Program
4d ago
Kezar Life Sciences trading resumes
Premium
The Fly
Kezar Life Sciences trading resumes
4d ago
Kezar says interim study required by FDA would delay future zetomipzomib trials
Premium
The Fly
Kezar says interim study required by FDA would delay future zetomipzomib trials
4d ago
Kezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)
PremiumThe FlyKezar Life Sciences reports Q2 EPS ($1.87), consensus ($2.32)
2M ago
Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties
Premium
Ratings
Cautious Hold on Kezar Life Sciences Amid Zetomipzomib Developments and Market Uncertainties
3M ago
Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial
Premium
The Fly
Kezar Life Sciences lifts partial clinical hold on PORTOLA Phase 2a trial
3M ago
Kezar Life Sciences Appoints New Principal Accounting Officer
PremiumCompany AnnouncementsKezar Life Sciences Appoints New Principal Accounting Officer
7M ago
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
Premium
Ratings
Kezar Life Sciences: Promising AIH Phase II Results and Strategic FDA Engagement Justify Buy Rating
7M ago
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
Premium
The Fly
Kezar Life Sciences price target lowered to $7 from $9 at Wells Fargo
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100